VTGN
VistaGen Therapeutics Inc
Halal Rating :
Last Price
$2.90
Last updated:
Market Cap
-
7D Change
-1.02%
1 Year Change
-42.0%
Company Overview
Industries
Exchange
Next Earnings Date
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders. Their lead product candidate is fasedienol (PH94B), a novel investigational nasal spray in development for the treatment of social anxiety disorder and other anxiety disorders.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $183000.0 | $14.41m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $84000.0 | $12.21m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $197900.0 | $11.56m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate VistaGen Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.